BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 2428840)

  • 1. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
    Niederau C; Liddle RA; Ferrell LD; Grendell JH
    J Clin Invest; 1986 Oct; 78(4):1056-63. PubMed ID: 2428840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis.
    Gomez G; Townsend CM; Green D; Rajaraman S; Uchida T; Thompson JC
    Surgery; 1989 Aug; 106(2):230-6; discussion 237-8. PubMed ID: 2474863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.
    Niederau C; Liddle RA; Williams JA; Grendell JH
    Gut; 1987; 28 Suppl(Suppl):63-9. PubMed ID: 2446964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the cholecystokinin receptor antagonist L-364,718 on pancreatitis induced by a deficient in choline and supplemented with ethionine (CDE) diet in the rat.
    Manso MA; Rodriguez AI; Garcia-Montero AC; De Dios I
    Arch Physiol Biochem; 1995 Aug; 103(4):410-5. PubMed ID: 8548474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats.
    Leonhardt U; Seidensticker F; Stöckmann F; Creutzfeldt W
    Pancreas; 1993 Jan; 8(1):98-102. PubMed ID: 7678329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.
    Nadella S; Ciofoaia V; Cao H; Kallakury B; Tucker RD; Smith JP
    Dig Dis Sci; 2020 May; 65(5):1376-1384. PubMed ID: 31598921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice.
    Suzuki M; Isaji S; Stanten R; Frey CF; Ruebner B
    Int J Pancreatol; 1992 Feb; 11(1):59-65. PubMed ID: 1374785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor.
    Niederau C; Crass RA; Silver G; Ferrell LD; Grendell JH
    Gastroenterology; 1988 Dec; 95(6):1648-57. PubMed ID: 3141239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice.
    Silverman M; Ilardi C; Bank S; Kranz V; Lendvai S
    Gastroenterology; 1989 Jan; 96(1):186-92. PubMed ID: 2462522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
    Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB
    Cancer Res; 1989 May; 49(9):2438-41. PubMed ID: 2706631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats.
    Song W; Yamaguchi H; Nakano I; Kimura T; Nawata H
    Fukuoka Igaku Zasshi; 1996 Jan; 87(1):14-22. PubMed ID: 8820983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early development of experimental biliary pancreatitis and its amelioration by CCK-receptor blockade.
    Niederau C; Borchard F; Lüthen R; Niederau M
    Hepatogastroenterology; 1996; 43(12):1442-53. PubMed ID: 8975946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term CCK stimulation and CCK blockade on pancreatic and intestinal growth, morphology, and function.
    Niederau C; Lüthen R; Niederau M; Strohmeyer G; Ferrell LD; Grendell JH
    Digestion; 1990; 46 Suppl 2():217-25. PubMed ID: 2262055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    Jia D; Yamamoto M; Otsuki M
    World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
    Makovec F; Bani M; Cereda R; Chistè R; Revel L; Rovati LC; Setnikar I; Rovati LA
    Peptides; 1986; 7(6):1159-64. PubMed ID: 3104890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Pancreas Study Group: Inhibition of pancreas secretion and trypsin activity. Mechanisms and importance of therapy of acute and chronic pancreatitis].
    Z Gastroenterol Verh; 1987 Apr; 22():132-55. PubMed ID: 2442904
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.